<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388621</url>
  </required_header>
  <id_info>
    <org_study_id>GMIHO-008/2009_AG56</org_study_id>
    <secondary_id>2010-018849-59</secondary_id>
    <nct_id>NCT01388621</nct_id>
  </id_info>
  <brief_title>Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer</brief_title>
  <acronym>PROVE</acronym>
  <official_title>PROVE A Randomized Phase II Trial of Standard Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>WiSP Wissenschaftlicher Service Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to estimate the therapeutic efficacy of the experimental
      targeted regimen including the EGFR antibody panitumumab (in combination with carboplatin and
      either pegylated liposomal doxorubicin or gemcitabine) in relation to the respective standard
      combination in patients with a KRAS wildtype with platinum-sensitive recurrent ovarian
      cancer. It is expected that the progression free survival rate at 12 months is improved by
      the targeted regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate after 12 months.</measure>
    <time_frame>12 month</time_frame>
    <description>PFS is defined as the time from randomisation to the time of disease progression or relapse (according to RECIST, not CA-125 only!) or death, or to the date of last tumor assessment without any such event (censored observation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Tumor-Response</measure>
    <time_frame>Duration of Therapy (Therapy is planned for 6 cycles of 3 resp. 4 weeks each, shorter or longer durations are possible)</time_frame>
    <description>according to RECIST, including measurable disease patients only, and including patients with CA-125 defined disease as well</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>End of Follow-up (up to 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>End of Follow-up (up to 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum toxicity resp. AE grade per patient per toxicity resp. AE during therapy</measure>
    <time_frame>Duration of Therapy (Therapy is planned for 6 cycles of 3 resp. 4 weeks each, shorter or longer durations are possible)</time_frame>
    <description>Toxicities resp. (S)AE during therapy will be documented, reported and analyzed according to NCI CTC 3.0 with special focus on skin toxicity.
Results are given as maximum grade per patient per toxicity resp. AE during therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Rate</measure>
    <time_frame>Duration of Therapy (Therapy is planned for 6 cycles of 3 resp. 4 weeks each, shorter or longer durations are possible)</time_frame>
    <description>according to RECIST, including measurable disease patients only, and including patients with CA-125 defined disease as well</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm (A):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles
OR
Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles
The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard arm (B):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
OR
Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.</description>
    <arm_group_label>Experimental arm (A):</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles</description>
    <arm_group_label>Experimental arm (A):</arm_group_label>
    <arm_group_label>Standard arm (B):</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles</description>
    <arm_group_label>Experimental arm (A):</arm_group_label>
    <arm_group_label>Standard arm (B):</arm_group_label>
    <other_name>multiple generics in existence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles</description>
    <arm_group_label>Experimental arm (A):</arm_group_label>
    <arm_group_label>Standard arm (B):</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles</description>
    <arm_group_label>Experimental arm (A):</arm_group_label>
    <arm_group_label>Standard arm (B):</arm_group_label>
    <other_name>multiple generics in existence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.</description>
    <arm_group_label>Experimental arm (A):</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with pretreated epithelial ovarian cancer, primary peritoneal
             carcinomatosis or fallopian tube cancer with histological confirmation of the tumor

          -  Wild-type k-ras status

          -  Patients must have pretreated platinum-sensitive ovarian cancer with recurrence more
             than 6 months after completion of a platinum-containing regimen

          -  Presence of at least one measurable or non-measurable disease (e.g. malignant ascites)
             following RECIST criteria by radiologic evaluation OR histological confirmation of
             recurrence by biopsy. The presence of non-measurable lesions only requires in addition
             a 2-fold increase of CA-125 elevation above normal lab value (confirmed by two
             measurements).

          -  No more than 2 prior treatment regimens for these epithelial cancers

          -  Age &gt; 18 years.

          -  ECOG Performance Status of 0 or 1

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

               -  Hemoglobin &gt; 9.0 g/dl

               -  Leukocyte count &gt;3.000/mm3 ; absolute neutrophil count (ANC) &gt;1.500/mm3

               -  Platelet count ≥ 100.000/μl

               -  Total bilirubin &lt; 1,0 times the upper limit of normal

               -  ALT and AST &lt; 2,5 x upper limit of normal (&lt; 5 x upper limit of normal for
                  patients with liver involvement of their cancer)

               -  Alkaline phosphatase &lt; 4 x ULN

               -  PT-INR/PTT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically
                  anticoagulated with an agent such as coumarin or heparin will be allowed to
                  participate provided that no prior evidence of underlying abnormality in these
                  parameters exists.]

               -  Serum creatinine &lt; 1.5 x upper limit of normal and creatinine clearance &gt; 50
                  ml/min.

               -  Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal

          -  Signed and dated informed consent before the start of specific protocol procedures.

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease (incl. myocardial infarction, unstable
             angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia)
             ≤ 1 year before enrolment.

          -  History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan.

          -  History of HIV infection or chronic hepatitis B or C

          -  Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0)

          -  Pre-existing neuropathy &gt; grade 1 (NCI CTCAE), except for loss of tendon reflex

          -  Prior radiological or clinical evidence of CNS metastases including previously
             treated, resected, or asymptomatic brain lesions or leptomeningeal involvement by head
             CT scan or MRI

          -  Patients with seizure disorder requiring medication (such as steroids or
             anti-epileptics)

          -  History of organ allograft

          -  Patients with evidence or history of bleeding diathesis

          -  Patients undergoing renal dialysis

          -  Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively
             treated &gt; 3 years prior to study entry.

          -  Patients in a closed institution according to an authority or court decision

          -  Any condition that is unstable or could jeopardize the safety of the patient and their
             compliance in the study

        Excluded therapies and medications, previous and concomitant:

          -  Anticancer chemotherapy within 4 weeks prior to study entry.

          -  Prior anti-EGFR therapy

          -  Radiotherapy during study or within 4 weeks of start of study drug. (Palliative
             radiotherapy of non-target lesions will be allowed) and prior radiotherapy of &gt; 25% of
             the bone marrow

          -  Major surgery within 4 weeks of start of study

          -  Autologous bone marrow transplant or stem cell rescue within 12 months of study

          -  Investigational drug therapy outside of this trial during or within 4 weeks of study
             entry

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalid Sehouli, MD (Prof. Dr. med.)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frauenklinik Charité - Universitätsmedizin Berlin Campus Virchow-Klinikum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadine Albers</last_name>
    <phone>0351-25933-281</phone>
    <email>nadine.albers@gmiho.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <state>Baden Württemberg</state>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ekkehard von Abel, Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Oettle</name>
      <address>
        <city>Friedrichshafen</city>
        <state>Baden-Württemberg</state>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helmut Oettle, MD (PD Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus Frauenklinik</name>
      <address>
        <city>Cottbus</city>
        <state>Brandenburg</state>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrzej Popiela, MD (Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Heinrich</name>
      <address>
        <city>Fuerstenwalde</city>
        <state>Brandenburg</state>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Heinrich, MD (Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik am Klinikum Südstadt</name>
      <address>
        <city>Rostock</city>
        <state>mecklenburg-Vorpommern</state>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MVM mbH Onkologische Schwerpunktpraxis Leer</name>
      <address>
        <city>Leer</city>
        <state>Niedersachsen</state>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lothar Müller, MD (Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn-Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian M Kurbacher, MD (PD Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg Zentrum für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans-Georg Strauss, MD (Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Kahl, MD (PD Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz Frauen- und Kinderklinik</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Petra Krabisch, MD (Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schilling / Till / Kohn FÄ f. Gynäkologie u. Geburtshilfe, Gynäkol.-Onkol. Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jörg Schilling, MD (Dr.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Frauenheilkunde</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Klare, MD (Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynäkologische Praxis Dr. med. Ruhmland</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Birgit Ruhmland, MD (Dr.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park-Klinik Weißensee</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elke Keil, MD (Dr.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin - Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Charité - Universitätsmedizin Berlin Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jalid Sehouli, MD (Prof. Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ev. Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jochem Potenberg, MD (Dr. med)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tagesklinik Altonaer Strasse</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Nugent, MD (Dr. med.)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>July 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>August 19, 2013</last_update_submitted>
  <last_update_submitted_qc>August 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian cancer</keyword>
  <keyword>recurrent</keyword>
  <keyword>platinum-sensitive</keyword>
  <keyword>KRAS-Wildtype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

